Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014;15(15):1903-30.
doi: 10.2217/pgs.14.147.

Pharmacogenomics of antimicrobial agents

Ar Kar Aung  1 , David W Haas, Todd Hulgan, Elizabeth J Phillips
Affiliations
Review

Pharmacogenomics of antimicrobial agents

Ar Kar Aung et al. Pharmacogenomics. 2014.

Abstract

Antimicrobial efficacy and toxicity varies between individuals owing to multiple factors. Genetic variants that affect drug-metabolizing enzymes may influence antimicrobial pharmacokinetics and pharmacodynamics, thereby determining efficacy and/or toxicity. In addition, many severe immune-mediated reactions have been associated with HLA class I and class II genes. In the last two decades, understanding of pharmacogenomic factors that influence antimicrobial efficacy and toxicity has rapidly evolved, leading to translational success such as the routine use of HLA-B*57:01 screening to prevent abacavir hypersensitivity reactions. This article examines recent advances in the field of antimicrobial pharmacogenomics that potentially affect treatment efficacy and toxicity, and challenges that exist between pharmacogenomic discovery and translation into clinical use.

Keywords: antibacterials; antifungals; antimalarials; antivirals; pharmacogenomics.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Complex relationships between various drug, pathogen and host factors affecting antimicrobial treatment outcome
ADR: Adverse drug reaction; PD: Pharmacogenomics; PK: Pharmacokinetics Modified and reproduced with written permission from Pharmacogenomics and Personalized Medicine [9].
Figure 2
Figure 2. Isoniazid metabolic pathways
GST: Gluthathione-S-transferase; NAT: N-acetyl transferase.
See this image and copyright information in PMC

References

    1. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380(9859):2224–2260. - PMC - PubMed
    1. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987–2015. - PMC - PubMed
    1. Davison DB, Barrett JF. Antibiotics and pharmacogenomics. Pharmacogenomics. 2003;4(5):657–665. - PubMed
    1. McNicholl JM, Downer MV, Udhayakumar V, Alper CA, Swerdlow DL. Host-pathogen interactions in emerging and re-emerging infectious diseases: a genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera. Annu Rev Public Health. 2000;21(1):15–46. - PubMed
    1. Tan SL, Ganji G, Paeper B, Proll S, Katze MG. Systems biology and the host response to viral infection. Nat Biotechnol. 2007;25(12):1383–1389. - PMC - PubMed

Publication types

MeSH terms